000105 KSC Week ended 07 Aug 2026

Weekly Investor Report

Yuhan Corporation · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 66,300 KRW
6.6% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -15.0% below the Trend Line and sits at 18.7% of its 52-week range. The latest completed week returned 6.6%, after a 13.9% four-week move. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.

Setup score 26 out of 100
Latest Close 66,300 KRW 7 Aug 2026
1W Return 6.6% latest completed week
4W Return 13.9% short-term follow-through
12W Return -9.4% quarterly tape
Trend Breadth 26.9% 14 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.6% Latest completed week; four-week move 13.9%. Indicator stack 15/46 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.18% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 1 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -15.0% below the Trend Line and sits at 18.7% of its 52-week range. The latest completed week returned 6.6%, after a 13.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.04

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 13.9% over four weeks, -9.4% over 12 weeks, and -35.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W6.6%
4W13.9%
12W-9.4%
26W-27.3%
52W-35.3%
Active trend streak0 weeks
Active weeks in one year14
Trend breadth26.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.52Latest activity-pressure read.
Pressure change67.7%Four-week change in activity pressure.
Leadership-44.28Latest relative-leadership reading.
RS change29.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

A published fundamentals and factor snapshot is not available for this company.

Open full factor analysis

No published fundamental snapshot is available for this company.

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 1 relevant articles.

0 positive · 1 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-42.1%Distance below the 52-week high.
13-week volatility4.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2615 weeks finished lower.
Best week+8.1%Week of 24 Jul.
Worst week-8.0%Week of 26 Jun.
Latest week+6.6%Week of 7 Aug.

Shape of recent returns

Strong gains2
Modest gains8
Flat weeks1
Modest losses7
Sharp losses8
Recent vol4.6%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split17/33Count of positive and negative weeks in the 52-week window.
Average skew3.0% / -2.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis10/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.07; No reversal markers Next-Week ExpectancyNegative 43.18%

Next-week expectancy is negative with a 43.18% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100

No published factor snapshot is available yet.

 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 1 relevant articles.

Yuhan Corporation's new lung cancer drug "Leklaza" is growing its presence in Johnson & Johnson'.. Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202666,300 KRW6.6%78,037 KRW87,570 KRW-0.52-44.285.0KOff
31 Jul 202662,200 KRW-2.4%79,192 KRW87,539 KRW-0.99-51.456.8KOff
24 Jul 202663,700 KRW8.1%80,494 KRW87,525 KRW-1.29-52.077.8KOff
17 Jul 202658,900 KRW1.2%81,782 KRW87,484 KRW-1.54-57.485.9KOff
10 Jul 202658,200 KRW-3.0%83,264 KRW87,465 KRW-1.61-62.586.6KOff
3 Jul 202660,000 KRW1.9%84,785 KRW87,433 KRW-1.64-65.081.5KOff
26 Jun 202658,900 KRW-8.0%86,246 KRW87,389 KRW-1.65-67.742.5KOff
19 Jun 202664,000 KRW0.0%87,817 KRW87,356 KRW-1.62-68.133.2KOff
12 Jun 202664,000 KRW-4.3%89,132 KRW87,288 KRW-1.52-65.242.5KOff
5 Jun 202666,900 KRW-6.6%90,751 KRW87,218 KRW-1.34-64.593.5KOff
29 May 202671,600 KRW-4.3%91,864 KRW87,135 KRW-1.17-64.3010.6KOff
22 May 202674,800 KRW2.2%92,955 KRW87,026 KRW-1.05-60.6113.9KOff
15 May 202673,200 KRW0.3%93,900 KRW86,890 KRW-1.01-60.5028.1KOff
8 May 202673,000 KRW-4.7%94,924 KRW86,762 KRW-1.14-61.4533.1KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context